

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On August 8, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]



PATENT
018781-004110US
T99-021

116-2
112

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEHMANN and SHIAU

Application No.: 09/760,364

Filed: January 12, 2001

For: CAR MODULATORS:
SCREENING AND TREATMENT OF
HYPERCHOLESTEROLEMIA

Examiner: Not yet assigned

Art Unit: 1646

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Nonprovisional Application mailed March 8, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

In the Specification:

Please replace the paragraph beginning at page 5, line 13 with the following:

--Figure 1 is a schematic of an approach for the disruption of the mouse CAR β gene.

The mouse cDNA is shown schematically, with the ATG denoting the start codon. The small bar